—
R&D expenses rose 11% to $5.6 million, primarily due to costs associated
with the BL-8040 GENESIS and COMBAT/KEYNOTE-202 clinical trials. Results
expected by the end of the year.
— BLRX
shares are down 75% so far this year.
ADVERTISEMENT
Market News
BioLineRx (BLRX): Q3 2019 Earnings Snapshot
— BiolineRX (NASDAQ: BLRX) reported third quarter 2019 operating loss of $6.6 million vs. $6.2 million loss in the year-over period. — Net loss per share was cents per share, narrower than a loss of 6 cents per share last year, due to higher share count. — R&D expenses rose 11% to $5.6 million, primarily […]
NYSE
$BLRX · Earnings
“— BiolineRX (NASDAQ: BLRX) reported third quarter 2019 operating loss of $6.6 million vs. $6.2 million loss in the year-over period. — Net loss per share was cents per share, narrower than a loss of 6 cents per share last year, due to higher share count. — R&D expenses rose 11% to $5.6 million, primarily […]
· November 11, 2019
— BiolineRX (NASDAQ: BLRX) reported third
quarter 2019 operating loss of $6.6 million vs. $6.2 million loss in the
year-over period.
— Net
loss per share was cents per share, narrower than a loss of 6 cents per share
last year, due to higher share count.
ADVERTISEMENT